Alliance Pharma PLC has released its Block Listing Six Monthly Return, covering the period from 28 December 2023 to 28 June 2024. The return details the number of securities originally admitted, the balance of unallotted securities under schemes from the previous return, and the amount by which the block schemes have been increased. It also outlines the number of securities issued/allotted under schemes during the period and the balance under schemes not yet issued/allotted at the end of the period.
The company's schemes include The Alliance Pharma plc Approved Share Option Plan 2005, The Alliance Pharma plc Share Option Plan 2006, The Alliance Pharma plc Company Share Option Plan 2015, and The Alliance Pharma plc Long-Term Incentive Plan 2019. The contact person for further information is Chris Chrysanthou, the Company Secretary, and the telephone number provided is +44 (0)1249 705166.
Alliance Pharma plc is a growing consumer healthcare company listed on AIM (APH). The company's purpose is to empower people to make a positive difference to their health and wellbeing by making trusted and proven brands available worldwide. The company focuses on delivering organic growth through investing in priority brands and channels, related innovation, and selective geographic expansion. Additionally, it may consider enhancing organic growth through selective, complementary acquisitions.
For further information, the company can be contacted at + 44 (0)1249 466966, and the Head of Investor Relations is Cora McCallum, who can be reached at + 44 (0)1249 705168 or via email at [email protected]. The company's media contacts are Burson Buchanan and Deutsche Numis (Nominated Adviser and Joint Broker), and Investec Bank plc (Joint Broker).
This summary provides an overview of Alliance Pharma PLC's Block Listing Six Monthly Return and its core business activities, as outlined in the provided news release.